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cinomIntroduction
Malignant germ cell tumor is an uncommon type of ovarian can-
cer that accounts for fewer than 5%of total ovarian cancers.1 Yolk sac
umors (YSTs) of the ovary, also called endodermal sinus tumors
ESTs), are rare and highly malignant germ cell tumors of utmost
mportance, occurring in children and young adults2; they are char-
acterized by endodermal differentiation.3 YSTs represent about
.3% of malignant germ cell tumors.4 YSTs coexisting with a variety
f histologic patterns has been described but those with an epithelial
alignant component are extremely rare.5 We describe a rare case of
varian endometrioid adenocarcinoma with a YST component oc-
urring in a postmenopausal woman.
Case Report
We report a case of a 73-year-old woman. She observed an increase
in abdominal girth. An ultrasonogram showed a large unilateral right
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Clinical Pra
● Yolk sac tumors (YSTs) of the ovary are rare and highly
malignant germ cell tumors of utmost importance, oc-
curring in children and young adults. They are char-
acterized by endodermal differentiation.
● YSTs coexisting with a variety of histologic patterns
have been described but those with an epithelial ma-
lignant component are extremely rare, especially in
postmenopausal women.
● We describe a rare case of ovarian endometrioid ad-
enocarcinoma (EOC) with a YST component occurring
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http://dx.doi.org/10.1016/j.cogc.2012.05.003ovarianmass, which was confirmed by subsequent computed tomog-
raphy (CT). The patient underwent open abdominal surgical explora-
tion: Bilateral salpingo-oophorectomy and omentectomy were per-
formed. The pathologic examination resulted in a diagnosis of
endometrioid adenocarcinoma (EOC) with a YST component in the
right ovary (Figures 1, 2); cytologic examination of peritoneal fluid was
negative for neoplastic disease. She was staged as having pT1aN0M0
disease. Before surgery, tumormarkers (serum alpha-fetoprotein, cancer
antigen 125 [CA125], and carcinoembryonic antigen [CEA]) were not
elevated. After collegial discussion, considering the predominance of the
endometrioid adenocarcinoma component, we decided on postopera-
tive treatment consisting of 6 courses of paclitaxel (175 mg/m2) and
carboplatin (AUC4). The patient was treated with chemotherapy with-
out any problems. At 22-months’ follow-up, the patient was free of
recurrence. CT results were normal and tumor markers (serum alpha-
fetoprotein, CA125, and CEA) were not elevated.
Discussion
We describe a rare case of ovarian endometrioid adenocarcinoma
(EOC) with a YST component occurring in a 73-year-old woman.
Twenty-four cases of the coexistence of EOC and YST in postmeno-
pausal women have been reported in the literature6 and of them, our
atient had the longest disease-free survival.7,8 The clinicopathologic
ice Points
in a 73-years-old woman (pT1aN0M0) that was
treated with a combination of paclitaxel and carbopla-
tin for 6 cycles. At 22-months’ follow-up, the patient
was free of recurrence. This is the longest disease-
free survival seen when compared with other reported
cases in the literature.
● No conclusions could be drawn from this case report;
we hope that other authors describe their experiences
to define the most appropriate approach to this rare
tumor.
o. 1, 31-2 © 2012 Elsevier Inc. All rights reserved.
a, Ovarian cancer, Yolk sac tumorct
5, Nprofile of YST arising in association with EOC differs from that of pure
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Ovarian YST Component in a Postmenopausal Woman
32 CYST.7 It is reported that the development of extraembryonal germ cell
issue from tumors of somatic origin is a rare event in the female genital
ract and occurs mainly in the aerodigestive and urinary tracts.9 There
re 4 different theories for this event: the teratoma theory, retrodifferen-
iation, the collision theory, and the neometaplasia theory.8,10,11 Neo-
metaplasia, also called aberrant differentiation, is the most reasonable
theory to explain thehistogenesis of this tumor: somatic carcinomashave
the capability for germ cell differentiation, and the germ cell component
is thought to derive from somatic mesodermal cells and not from germ
cells.7 Clinically these tumors are characterized by rapid growth and
extensive intraabdominal spread. The patients usually present with ab-
dominal pain, a palpablemass, abdominal distention, and vaginal bleed-
ing.1 Because of its rarity, YST prognostic factors remain unclear; the
tage, an ascites volumeof100mL, and a residual tumormeasuring
cm tend to affect the prognosis of YSTpositively.12 Also, tumormark-
Figure 1 Endometrioid Adenocarcinoma With a Yolk Sac
Tumor Component in Right Ovary
Figure 2 Endometrioid Adenocarcinoma With a Yolk Sac
Tumor Component in Right Ovaryrs such as alpha fetoprotein and human chorionic gonadotropin are
linical Ovarian & Other Gynecologic Cancer June 2012onsidered in the prognostic factors.13 There are no randomized studies
elating to the management of YST of the ovary; there are only retro-
pective reviews and single case reports. Surgical diagnosis and treatment
onsists of laparotomy with bilateral salpingo-oophorectomy, omentec-
omy, multiple peritoneal and abdominal biopsies, peritoneal cytologic
tudies, and resection of all visible disease. BEP (bleomycin, etoposide,
isplatin) is the current standard therapy for ovarian germ cell tumors.2,9
Chemotherapy is effective for pure YST;14 we do not know if YSTwith
OC responds to chemotherapy5 or which kind of chemotherapy.
After collegial discussion and considering that our patient’s disease
s more similar to EOC than to YST (seeing a preponderance of the
OC component), we chose a combination of paclitaxel and carbo-
latin for 6 cycles. In 1 study, it was believed that regimens for YST
ay be appropriate in these rare tumors;8 other studies used a com-
ination of BEP and paclitaxel and carboplatin, concluding that this
articular tumor is more similar to EOC than to YST in clinical
ehavior and suggesting that a combination of paclitaxel and carbo-
latin should be compared with BEP.7 Other authors also reported
that neoplasms with a YST component in older women are less re-
sponsive to the chemotherapy used for ovarian germ cell tumors, and
adjuvant therapy should include aggressive platinum-based chemo-
therapy designed to treat both epithelial ovarian cancer and germ cell
tumors. These authors reported that 2 recent patients with stage 1
disease (as in our patient) treated aggressively with platinum-based
chemotherapy are living and have been disease free  1 year after
operation.6 Finally, no conclusion could be drawn from this case
eport; we hope that other authors describe their experiences to de-
ne the most appropriate approach to this rare tumor.
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